Acadian Asset Management LLC Cuts Stake in Organogenesis $ORGO

Key Points

• Acadian Asset Management LLC reduced its stake in Organogenesis by 24.4%, now holding 2,333,245 shares valued at approximately $10.07 million.
• Organogenesis reported a quarterly earnings miss with an EPS of ($0.09), falling short of analysts' estimates and revenue expectations.
• Analysts are optimistic about Organogenesis, with Cantor Fitzgerald raising its price target from $7.00 to $9.00 and a consensus rating of "Moderate Buy" on the stock.

Acadian Asset Management LLC cut its stake in Organogenesis (NASDAQ:ORGO - Free Report) by 24.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,333,245 shares of the company's stock after selling 751,458 shares during the quarter. Acadian Asset Management LLC owned 1.84% of Organogenesis worth $10,067,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in ORGO. Driehaus Capital Management LLC bought a new stake in shares of Organogenesis in the first quarter worth approximately $7,756,000. Invesco Ltd. grew its stake in shares of Organogenesis by 779.7% in the first quarter. Invesco Ltd. now owns 1,069,252 shares of the company's stock worth $4,619,000 after acquiring an additional 947,705 shares during the period. Vanguard Group Inc. grew its stake in shares of Organogenesis by 23.4% in the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company's stock worth $19,144,000 after acquiring an additional 841,618 shares during the period. Soleus Capital Management L.P. grew its stake in shares of Organogenesis by 5.4% in the fourth quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company's stock worth $39,952,000 after acquiring an additional 645,000 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of Organogenesis by 1,158.6% in the first quarter. SG Americas Securities LLC now owns 525,421 shares of the company's stock worth $2,270,000 after acquiring an additional 483,675 shares during the period. 49.57% of the stock is currently owned by institutional investors.

Organogenesis Trading Down 2.2%

ORGO opened at $4.93 on Friday. The company has a market cap of $625.41 million, a price-to-earnings ratio of -35.21 and a beta of 1.75. The company's 50 day moving average is $4.70 and its 200 day moving average is $4.28. Organogenesis has a 12-month low of $2.61 and a 12-month high of $6.71.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08). The business had revenue of $101.01 million during the quarter, compared to analysts' expectations of $104.75 million. Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%. Organogenesis has set its FY 2025 guidance at EPS. As a group, analysts predict that Organogenesis will post -0.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Cantor Fitzgerald lifted their price target on shares of Organogenesis from $7.00 to $9.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. BTIG Research reiterated a "buy" rating on shares of Organogenesis in a research note on Tuesday, July 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $7.50.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.

Want to see what other hedge funds are holding ORGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organogenesis (NASDAQ:ORGO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.